{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T10:28:39Z","timestamp":1746786519370},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00115-017-0350-y","type":"journal-article","created":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T12:12:23Z","timestamp":1496319143000},"page":"736-743","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risikogene bei Myopathien und mitochondrialen Erkrankungen"],"prefix":"10.1007","volume":"88","author":[{"given":"C.","family":"Stendel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. C.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Klopstock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,1]]},"reference":[{"key":"350_CR1","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1093\/brain\/awp236","volume":"132","author":"FL Norwood","year":"2009","unstructured":"Norwood FL et al (2009) Prevalence of genetic muscle disease in Northern England: in-depth analysis of a\u00a0muscle clinic population. Brain 132:3175\u20133186","journal-title":"Brain"},{"key":"350_CR2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1212\/WNL.0b013e318207afeb","volume":"76","author":"E Pegoraro","year":"2011","unstructured":"Pegoraro E, Hoffman EP, Piva L et\u00a0al (2011) SPP1 genotype is a\u00a0determinant of disease severity in Duchenne muscular dystrophy. Neurology 76:219\u2013226","journal-title":"Neurology"},{"key":"350_CR3","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ana.23819","volume":"73","author":"KM Flanigan","year":"2013","unstructured":"Flanigan KM, Ceco E, Lamar KM et\u00a0al (2013) LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy. Ann Neurol 73:481\u2013488","journal-title":"Ann Neurol"},{"key":"350_CR4","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1172\/JCI118101","volume":"96","author":"P Bernasconi","year":"1995","unstructured":"Bernasconi P, Torchiana E, Confalonieri P et al (1995) Expression of the transforming factor-beta 1 in dystrophic patient muscles correlates with fibrosis. J\u00a0Clin Invest 96:1137\u20131144","journal-title":"J Clin Invest"},{"key":"350_CR5","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1172\/JCI37662","volume":"119","author":"SA Vetrone","year":"2009","unstructured":"Vetrone SA, Montecino-Rodriguez E, Kudryashova E et al (2009) Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J\u00a0Clin Invest 119:1583\u20131594","journal-title":"J Clin Invest"},{"key":"350_CR6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/7675","volume":"21","author":"K North","year":"1999","unstructured":"North K et al (1999) A common nonsense mutation results in alpha-actinin-3-deficiency in the general population. Nat Genet 21:353\u2013354","journal-title":"Nat Genet"},{"key":"350_CR7","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1086\/377590","volume":"73","author":"N Yang","year":"2003","unstructured":"Yang N et\u00a0al (2003) ACTN3 genotype is associated with human elite performance. Am J Hum Genet 73:627\u2013631","journal-title":"Am J Hum Genet"},{"key":"350_CR8","doi-asserted-by":"crossref","first-page":"14143","DOI":"10.1038\/ncomms14143","volume":"8","author":"MW Hogarth","year":"2017","unstructured":"Hogarth MW, Houweling PJ, Thomas KC et\u00a0al (2017) Evidence for ACTN3 as a\u00a0genetic modifier of Duchenne muscular dystrophy. Nat Commun 8:14143","journal-title":"Nat Commun"},{"key":"350_CR9","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181f96175","volume":"75","author":"JC Greef De","year":"2010","unstructured":"De Greef JC, Lemmers RJ, Camano P et\u00a0al (2010) Clinical features of facioscapulohumeral muscular dystrophy 2. Neurology 75:1548\u20131554","journal-title":"Neurology"},{"key":"350_CR10","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ng.2454","volume":"44","author":"RJ Lemmers","year":"2012","unstructured":"Lemmers RJ, Tawil R, Petek LM et al (2012) Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes saciosapulohumeral muscular dystrophy type 2. Nat Genet 44:1370\u20131374","journal-title":"Nat Genet"},{"key":"350_CR11","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ajhg.2013.08.004","volume":"93","author":"S Sacconi","year":"2013","unstructured":"Sacconi S, Lemmers RJLF, Balog J et\u00a0al (2013) The FSHD2 gene SMCHD1 is a\u00a0modifier of disease severity in families affected by FSHD1. Am J Hum Genet 93:744\u2013751","journal-title":"Am J Hum Genet"},{"issue":"2","key":"350_CR12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ijcard.2011.10.128","volume":"166","author":"RA Ribeiro","year":"2011","unstructured":"Ribeiro RA, Ziegelmann PK, Duncan BB et al (2011) Impact of statin dose on major cardiovascular events: a mixed treatment comparison meta-analysis involving more than 175,000 patients. Int J Cardiol 166(2):431\u2013439","journal-title":"Int J Cardiol"},{"key":"350_CR13","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s00210-006-0040-y","volume":"372","author":"J K\u00f6nig","year":"2006","unstructured":"K\u00f6nig J, Seithel A, Gradhand U, Fromm MF (2006) Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 372:432\u2013443","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"350_CR14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","volume":"359","author":"E Link","year":"2008","unstructured":"SEARCH Collaborative Group, Link E, Parish H, Armitage J et al (2008) SLCO1B1 variants and statin-induced myopathy \u2013 a\u00a0genome wide study. N\u00a0Eng J Med 359:789\u2013799","journal-title":"N Eng J Med"},{"key":"350_CR15","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.clpt.2005.08.003","volume":"78","author":"M Fiegenbaum","year":"2005","unstructured":"Fiegenbaum M, da Silveira FR, Van der San CR et al (2005) The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 78:551\u2013558","journal-title":"Clin Pharmacol Ther"},{"key":"350_CR16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nmd.2013.09.011","volume":"24","author":"M Needham","year":"2014","unstructured":"Needham M, Mastaglia FL (2014) Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord 24:4\u201315","journal-title":"Neuromuscul Disord"},{"key":"350_CR17","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/ng1776","volume":"38","author":"S Calvo","year":"2006","unstructured":"Calvo S, Jain M, Xie X et\u00a0al (2006) Systematic identification of human mitochondrial disease genes through integrative genomics. Nat Genet 38:576\u2013582","journal-title":"Nat Genet"},{"issue":"3","key":"350_CR18","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10545-015-9823-y","volume":"38","author":"SB Wortmann","year":"2015","unstructured":"Wortmann SB, Koolen DA, Smeitink JA et\u00a0al (2015) Whole exome sequencing of suspected mitochondrial patients in clinical practice. J\u00a0Inherit Metab Dis 38(3):437\u2013443","journal-title":"J Inherit Metab Dis"},{"key":"350_CR19","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1126\/science.3201231","volume":"242","author":"DC Wallace","year":"1988","unstructured":"Wallace DC, Singh G, Lott MT et\u00a0al (1988) Mitochondrial DNA mutation associated with Leber\u2019s hereditary optic neuropathy. Science 242:1427\u20131430","journal-title":"Science"},{"key":"350_CR20","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1093\/brain\/awp158","volume":"132","author":"MA Kirkman","year":"2009","unstructured":"Kirkman MA, Yu-Wai-Man P, Korsten A et al (2009) Gene-environment interactions in Leber hereditary optic neuropathy. Brain 132:2317\u20132326","journal-title":"Brain"},{"key":"350_CR21","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/brain\/awq276","volume":"134","author":"C Giordano","year":"2011","unstructured":"Giordano C, Montopoli M, Perli E et\u00a0al (2011) Oestrogens ameliorate mitochondrial dysfunction in Leber\u2019s hereditary optic neuropathy. Brain 134:220\u2013234","journal-title":"Brain"},{"key":"350_CR22","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/hmg\/ddv498","volume":"25","author":"P Jiang","year":"2016","unstructured":"Jiang P, Jin X, Peng Y et al (2016) The exome sequencing identified the mutation in YARS2 encoding the mitochondrial tyrosyl-tRNA synthetase as a\u00a0nuclear modifier for the phenotypic manifestation of Leber\u2019s hereditary optic neuropathy-associated mitochondrial DNA mutation. Hum Mol Genet 25:584\u2013596","journal-title":"Hum Mol Genet"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-017-0350-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-017-0350-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-017-0350-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,4]],"date-time":"2017-07-04T15:34:42Z","timestamp":1499182482000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-017-0350-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,1]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["350"],"URL":"https:\/\/doi.org\/10.1007\/s00115-017-0350-y","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,1]]}}}